Delcath Systems Inc
NASDAQ:DCTH
Net Margin
Delcath Systems Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Delcath Systems Inc
NASDAQ:DCTH
|
390.1m USD |
-71%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
223.6B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
181.8B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
150.3B USD |
12%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
139.3B USD |
13%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
107.2B USD |
13%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
53.2B EUR |
9%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
59.2B USD |
8%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
44.3B USD |
75%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
260.4B CNY |
33%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
35B USD |
23%
|
Delcath Systems Inc
Glance View
Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. The company is headquartered in New York City, New York and currently employs 45 full-time employees. The company went IPO on 2000-10-19. The firm's lead product candidate, the HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) is a drug/device combination product. HEPZATO KIT is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, its commercial product is a medical device having the same device components as the HEZPATO KIT but without the melphalan hydrochloride, is designated as a Class III medical device, and is sold under the trade name CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT), where it is being used at various medical centers to treat a range of cancers of the liver. In the United States, HEPZATO KIT is considered a combination drug and device product. The firm's product administers concentrated regional chemotherapy to the liver.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Delcath Systems Inc's most recent financial statements, the company has Net Margin of -70.9%.
You don't have any saved screeners yet